# Odyssey Marine Exploration Inc: financial statements, quarterly

OMEX · Nasdaq · CIK 798528 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/omex.md) · [Financials](/companies/omex/financials.md) · [Filings](/companies/omex/filings.md) · [Insiders](/companies/omex/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/omex/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.2](/filings/0000950170-24-126269.md) | [(0.6) d](/filings/0001193125-24-141624.md) | [0.2](/filings/0000950170-25-069126.md) | [0.2](/filings/0000950170-25-110072.md) | [0.2](/filings/0001193125-25-275786.md) | [0.1 d](/filings/0001193125-26-134584.md) | [0.1](/filings/0001193125-26-219739.md) | [0.1](/filings/0001193125-26-344788.md) | [0.1](/filings/0001193125-25-275786.md) | [0.0 d](/filings/0001193125-26-134584.md) | [0.0](/filings/0001193125-26-219739.md) | [0.1](/filings/0001193125-26-344788.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [1.6](/filings/0000950170-24-126269.md) | [1.7 d](/filings/0000950170-25-047918.md) | [4.0](/filings/0000950170-25-069126.md) | [2.2](/filings/0000950170-25-110072.md) | [1.7](/filings/0001193125-25-275786.md) | [1.7 d](/filings/0001193125-26-134584.md) | [1.8](/filings/0001193125-26-219739.md) | [3.8](/filings/0001193125-26-344788.md) | [1.4](/filings/0001193125-25-275786.md) | [4.0 d](/filings/0001193125-26-134584.md) | [5.8](/filings/0001193125-26-219739.md) | [7.1](/filings/0001193125-26-344788.md) |
| Operating income | $m | [(2.5)](/filings/0000950170-24-126269.md) | [(2.2) d](/filings/0000950170-25-047918.md) | [(4.7)](/filings/0000950170-25-069126.md) | [(3.0)](/filings/0000950170-25-110072.md) | [(2.9)](/filings/0001193125-25-275786.md) | [(1.4) d](/filings/0001193125-26-134584.md) | [(2.2)](/filings/0001193125-26-219739.md) | [(4.4)](/filings/0001193125-26-344788.md) | [(2.1)](/filings/0001193125-25-275786.md) | [(4.7) d](/filings/0001193125-26-134584.md) | [(6.4)](/filings/0001193125-26-219739.md) | [(7.7)](/filings/0001193125-26-344788.md) |
| Interest expense | $m | [1.8](/filings/0000950170-24-126269.md) | [1.4 d](/filings/0001193125-24-141624.md) | [1.8](/filings/0001193125-24-141913.md) | [1.8](/filings/0000950170-24-093873.md) | [1.7](/filings/0001193125-25-275786.md) | [1.2 d](/filings/0001193125-26-134584.md) | [1.2](/filings/0001193125-26-219739.md) | [1.2](/filings/0001193125-26-344788.md) | [1.4](/filings/0001193125-25-275786.md) | [1.2 d](/filings/0001193125-26-134584.md) | [0.2](/filings/0001193125-26-219739.md) | [0.2](/filings/0001193125-26-344788.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-126269.md) | [0.0 d](/filings/0000950170-25-047918.md) | [0.0](/filings/0000950170-25-069126.md) | [0.0](/filings/0000950170-25-110072.md) | [0.0](/filings/0001193125-25-275786.md) | [0.0 d](/filings/0001193125-26-134584.md) | [0.0](/filings/0001193125-26-219739.md) | [0.0](/filings/0001193125-26-344788.md) | [0.0](/filings/0001193125-25-275786.md) | [0.0 d](/filings/0001193125-26-134584.md) | [0.0](/filings/0001193125-26-219739.md) | [0.0](/filings/0001193125-26-344788.md) |
| Net income | $m | [(3.8)](/filings/0000950170-24-126269.md) | [(8.2) d](/filings/0000950170-25-047918.md) | [3.5](/filings/0000950170-25-069126.md) | [(1.5)](/filings/0000950170-25-110072.md) | [18.7](/filings/0001193125-25-275786.md) | [(5.0) d](/filings/0001193125-26-134584.md) | [2.2](/filings/0001193125-26-219739.md) | [(14.8)](/filings/0001193125-26-344788.md) | [(13.1)](/filings/0001193125-25-275786.md) | [(17.4) d](/filings/0001193125-26-134584.md) | [0.3](/filings/0001193125-26-219739.md) | [(9.3)](/filings/0001193125-26-344788.md) |
| Diluted EPS | $ per share | [(0.19)](/filings/0000950170-24-126269.md) | not reported | [(0.18)](/filings/0000950170-25-069126.md) | [(0.07)](/filings/0000950170-25-110072.md) | [0.13](/filings/0001193125-25-275786.md) | not reported | [0.01](/filings/0001193125-26-219739.md) | [(0.48)](/filings/0001193125-26-344788.md) | [(0.31)](/filings/0001193125-25-275786.md) | not reported | [(0.04)](/filings/0001193125-26-219739.md) | [(0.16)](/filings/0001193125-26-344788.md) |
| Basic EPS | $ per share | [(0.19)](/filings/0000950170-24-126269.md) | not reported | [0.17](/filings/0000950170-25-069126.md) | [(0.07)](/filings/0000950170-25-110072.md) | [0.90](/filings/0001193125-25-275786.md) | not reported | [0.08](/filings/0001193125-26-219739.md) | [(0.48)](/filings/0001193125-26-344788.md) | [(0.31)](/filings/0001193125-25-275786.md) | not reported | [0.01](/filings/0001193125-26-219739.md) | [(0.16)](/filings/0001193125-26-344788.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:Revenues
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.5](/filings/0001193125-24-141624.md) | [4.0](/filings/0000950170-25-047918.md) | [2.1](/filings/0001193125-24-141913.md) | [7.6](/filings/0000950170-24-093873.md) | [2.9](/filings/0000950170-24-126269.md) | [4.8](/filings/0001193125-26-134584.md) | [2.5](/filings/0000950170-25-069126.md) | [3.6](/filings/0000950170-25-110072.md) | [5.8](/filings/0001193125-25-275786.md) | [3.5](/filings/0001193125-26-344788.md) | [2.1](/filings/0001193125-26-219739.md) | [2.3](/filings/0001193125-26-344788.md) |
| Current assets | $m | [1.3](/filings/0001193125-24-141624.md) | [4.9](/filings/0000950170-25-047918.md) | [2.7](/filings/0001193125-24-141913.md) | [8.0](/filings/0000950170-24-093873.md) | [3.2](/filings/0000950170-24-126269.md) | [5.8](/filings/0001193125-26-134584.md) | [3.1](/filings/0000950170-25-069126.md) | [4.0](/filings/0000950170-25-110072.md) | [6.2](/filings/0001193125-25-275786.md) | [4.4](/filings/0001193125-26-344788.md) | [2.8](/filings/0001193125-26-219739.md) | [2.9](/filings/0001193125-26-344788.md) |
| Total assets | $m | [18.7](/filings/0001193125-24-141624.md) | [22.8](/filings/0000950170-25-047918.md) | [20.6](/filings/0001193125-24-141913.md) | [26.3](/filings/0000950170-24-093873.md) | [21.8](/filings/0000950170-24-126269.md) | [18.5](/filings/0001193125-26-134584.md) | [15.8](/filings/0000950170-25-069126.md) | [16.6](/filings/0000950170-25-110072.md) | [17.7](/filings/0001193125-25-275786.md) | [15.8](/filings/0001193125-26-344788.md) | [13.4](/filings/0001193125-26-219739.md) | [13.2](/filings/0001193125-26-344788.md) |
| Current liabilities | $m | [28.6](/filings/0001193125-24-141624.md) | [31.5](/filings/0000950170-25-047918.md) | [32.9](/filings/0001193125-24-141913.md) | [37.8](/filings/0000950170-24-093873.md) | [31.0](/filings/0000950170-24-126269.md) | [22.5](/filings/0001193125-26-134584.md) | [23.1](/filings/0000950170-25-069126.md) | [31.0](/filings/0000950170-25-110072.md) | [16.4](/filings/0001193125-25-275786.md) | [11.7](/filings/0001193125-26-344788.md) | [13.3](/filings/0001193125-26-219739.md) | [25.1](/filings/0001193125-26-344788.md) |
| Total liabilities | $m | [94.6](/filings/0001193125-24-141624.md) | [109](/filings/0000950170-25-047918.md) | [112](/filings/0001193125-24-141913.md) | [120](/filings/0000950170-24-093873.md) | [98.5](/filings/0000950170-24-126269.md) | [97.6](/filings/0001193125-26-134584.md) | [95.3](/filings/0000950170-25-069126.md) | [107](/filings/0000950170-25-110072.md) | [101](/filings/0001193125-25-275786.md) | [91.4](/filings/0001193125-26-344788.md) | [84.2](/filings/0001193125-26-219739.md) | [93.2](/filings/0001193125-26-344788.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(24.9)](/filings/0001193125-24-141624.md) | [(32.5)](/filings/0000950170-25-047918.md) | [(35.1)](/filings/0001193125-24-141913.md) | [(35.7)](/filings/0000950170-24-093873.md) | [(16.1)](/filings/0000950170-24-126269.md) | [(16.2)](/filings/0001193125-26-134584.md) | [(13.9)](/filings/0000950170-25-069126.md) | [(52.8)](/filings/0000950170-25-110072.md) | [(45.4)](/filings/0001193125-25-275786.md) | [(37.6)](/filings/0001193125-26-344788.md) | [(32.8)](/filings/0001193125-26-219739.md) | [(41.7)](/filings/0001193125-26-344788.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,171) d](/filings/0000950170-24-126269.md) | [(1,429) d](/filings/0000950170-25-047918.md) | [(1,669)](/filings/0000950170-25-069126.md) | [5,635 d](/filings/0000950170-25-110072.md) | [(1,555) d](/filings/0001193125-25-275786.md) | [(1,769) d](/filings/0001193125-26-134584.md) | [(1,955)](/filings/0001193125-26-219739.md) | [(1,978) d](/filings/0001193125-26-344788.md) | [(2,095) d](/filings/0001193125-25-275786.md) | [(2,821) d](/filings/0001193125-26-134584.md) | [(3,832)](/filings/0001193125-26-219739.md) | [(4,671) d](/filings/0001193125-26-344788.md) |
| Capital expenditure | $k | [(317) d](/filings/0000950170-24-126269.md) | [768 d](/filings/0000950170-25-047918.md) | [104](/filings/0000950170-25-069126.md) | [(19.6) d](/filings/0000950170-25-110072.md) | [4.0 d](/filings/0001193125-25-275786.md) | [(4.0) d](/filings/0001193125-26-134584.md) | [0.0](/filings/0000950170-25-069126.md) | [0.0 d](/filings/0000950170-25-110072.md) | [1.6 d](/filings/0001193125-25-275786.md) | [14.5 d](/filings/0001193125-26-134584.md) | not reported | not reported |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [19.5](/filings/0000950170-22-025117.md) | [19.9](/filings/0001193125-24-141913.md) | [19.9](/filings/0000950170-24-093873.md) | [20.0](/filings/0000950170-24-126269.md) | [26.7](/filings/0000950170-25-069126.md) | [20.5](/filings/0000950170-25-110072.md) | [25.2](/filings/0001193125-25-275786.md) | [41.6](/filings/0001193125-26-219739.md) | [30.8](/filings/0001193125-26-344788.md) | [41.6](/filings/0001193125-25-275786.md) | [56.7](/filings/0001193125-26-219739.md) | [58.6](/filings/0001193125-26-344788.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 58,691,389 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344788.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.